Eratrectinib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Eratrectinib is an investigational new drug that is being developed by Jiangsu Vcare Pharmatech for the treatment of solid tumors. It is a Trk receptor antagonist targeting specifically TRKA, TRKB and TRKC. It has been approved in June 2026 for use in treating for solid tumors in China.
Eratrectinib is an investigational new drug that is being developed by Jiangsu Vcare Pharmatech for the treatment of solid tumors. It is a Trk receptor antagonist targeting specifically TRKA, TRKB and TRKC. It has been approved in June 2026 for use in treating for solid tumors in China.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370309205 under CC BY-SA 4.0; modifications have been made.